Composition of Certain Balance Sheet Items

3 Months Ended

Mar. 31, 2019

Balance Sheet Related Disclosures [Abstract]

Composition of Certain Balance Sheet Items

Inventory

The composition of inventory was as follows:



	March 31, 2019			December 31, 2018
	(in thousands)
Raw materials	$	2,055		$	4,195
Work in progress	6,936			5,624
Finished goods	6,369			6,423
Total inventory	15,360			16,242
Less strategic inventory classified as non-current	(10,360		)	(11,510		)
Total inventory classified as current	$	5,000		$	4,732

Because we rely on single-source manufacturers of both the active pharmaceutical ingredient (“API”) for Korlym and Korlym tablets, we have purchased and hold significant quantities of these materials. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic Inventory,” a long-term asset.

Other Accrued Liabilities

Other accrued liabilities consisted of the following:



	March 31, 2019		December 31, 2018
	(in thousands)
Government rebates	$	10,829	$	11,132
Accrued compensation	3,296		7,879
Income taxes payable	2,462		1,542
Legal fees	531		314
Professional fees	493		240
Accrued selling and marketing costs	699		261
Accrued manufacturing costs	70		2,032
Other	450		386
Total other accrued liabilities	$	18,830	$	23,786